Position in ERAS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$19,075,242
+$19,075,242 QoQ
Shares Held
1,041,225
Ownership
0.298%
of shares outstanding
% of Portfolio
0.76%
of 13F equity value
Holder Rank
#44
of 255 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Derivatives in ERAS
reported options exposure · as of Jun 30, 2026CallValue
$68,535,120
CallShares
3,741,000
PutValue
$13,245,360
PutShares
723,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Caption Management, LLC holds $249,760,911 across 78 Biotechnology names. ERAS ranks #3 (7.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CGON |
CG Oncology, Inc.
|
484,461 | $34,420,954 | |
| 2 | INSM |
INSMED Inc
|
236,000 | $25,162,320 | |
| 3 | ERAS |
Erasca, Inc.
This page
|
1,041,225 | $19,075,242 | |
| 4 | CELC |
Celcuity Inc.
|
170,000 | $17,785,400 | |
| 5 | DSGN |
Design Therapeutics, Inc.
|
1,118,098 | $16,178,878 | |
| 6 | MLYS |
Mineralys Therapeutics, Inc.
|
413,087 | $11,145,087 | |
| 7 | REPL |
Replimune Group, Inc.
|
783,873 | $8,677,474 | |
| 8 | TARS |
Tarsus Pharmaceuticals, Inc.
|
120,700 | $7,596,858 |
All Filings in ERAS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $19,075,242 | 1,041,225 | Shares | Sole | 2026-08-14 | |
| 2026-06-30 | $13,245,360 | 723,000 | Put | Sole | 2026-08-14 | |
| 2026-06-30 | $68,535,120 | 3,741,000 | Call | Sole | 2026-08-14 | |
| 2026-03-31 | $1,820,250 | 112,500 | Put | Sole | 2026-05-15 | |
| 2026-03-31 | $8,090,000 | 500,000 | Call | Sole | 2026-05-15 | |
| 2025-12-31 | $7,393,128 | 1,987,400 | Call | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||